Our latest news for ‘NAFLD’

We are proud to be leading the way in providing more patient-centric solutions for people with liver disease that helps them and their physician make informed decisions about their care.

Read our latest news to find out more about how we are helping to improve the understanding of liver disease.

LiverMultiScan® has achieved nationwide payer coverage for diagnosis and management of NAFLD and other established chronic liver diseases Posted: March 14, 2022

Perspectum partners with SimonMed to expand its impact on liver health and the clinical journey for patients with liver disease Posted: January 13, 2022

NAFLD NASH LiverMultiScan Liver Disease liverhealth Partnership

Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health Posted: November 1, 2021

NAFLD NASH Liver Disease liver cancer Pharma

Perspectum Announces Partnership with Datavant to Improve Clinical Trial Recruitment with Connected Data Posted: September 16, 2021

NAFLD NASH Liver Disease medtech

New study finds Perspectum®’s LiverMultiScan® may positively impact patient participation in liver disease care pathways Posted: September 13, 2021

NAFLD NASH Liver Disease LiverMultiScan

New publication: Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis Posted: June 16, 2021

NAFLD NASH Liver Disease New publication

New research demonstrates superior performance of LiverMultiScan® for identifying patients with NASH and fibrosis Posted: February 24, 2021

NASH NAFLD LiverMultiScan Liver Disease New publication

LiverMultiScan® could be an alternative to liver biopsy for NASH clinical trials. Posted: February 4, 2021

NAFLD NASH LiverMultiScan New publication ClinicalTrials

Perspectum’s RADIcAL1 trial - addressing the health economic burden of invasive diagnostics for NAFLD and NASH Posted: December 9, 2020

RADIcAL NAFLD NASH LiverMultiScan Liver Disease New publication